 Open-market stock repurchases which greatly add to the long-term demand for shares in the market are likely to affect prices as long as the repurchase operations continue.For example, AstraZeneca embarked on an $11 billion share repurchase in 2011 and 2012 in a market which they estimated had an annual turnover of $30 billion, when excluding short-term share transactions.AstraZeneca claimed at the 2013 AGM that their open market interventions would not have temporary price effects whilst the interventions continued, but offered no evidence.